SINO BIOPHARM(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01177 SINO BIOPHARM

Closed 01-12 16:08:30

6.850

+0.020

+0.29%

High6.930	Low6.700	Vol75.46M
Open6.870	D1 Closing6.830	Amplitude3.37%
Mkt Cap128.51B	Tradable Cap128.51B	Total Shares18.76B
T/O514.97M	T/O Rate0.40%	Tradable Shares18.76B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"SINO BIOPHARM","latestPrice":6.85,"timestamp":1768205310003,"preClose":6.83,"halted":0,"volume":75463757,"delay":0,"floatShares":18761000000,"shares":18761000000,"eps":0.21417632511850562,"marketStatus":"Closed","change":0.02,"latestTime":"01-12 16:08:30","open":6.87,"high":6.93,"low":6.7,"amount":514967715,"amplitude":0.033675,"askPrice":6.85,"askSize":563000,"bidPrice":6.84,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":0.23937953243310675,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":6.83,"dividendRate":0.013388,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.836018,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3843,"impliedVolPercentile":0.1707},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2602538750","title":"Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Fresh IPF And Psoriasis Trial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602538750","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602538750?lang=en_us&edition=fundamental","pubTime":"2026-01-10 17:26","pubTimestamp":1768037175,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906.\nSee our latest analysis for Sino Biopharmaceutical.\nThe latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-fr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-fr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","HK0000165453.HKD","BK1589","IE00BZ08YS42.EUR","DCF","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","BK1191"],"gpt_icon":0},{"id":"2601873831","title":"Sino Biopharmaceutical Stock Rallies 3.8% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2601873831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601873831?lang=en_us&edition=fundamental","pubTime":"2026-01-07 16:30","pubTimestamp":1767774600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rose 3.8% to 6.83 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 26458.95.This was the stock's fourth consecutive day of gains.Sino Biopharmaceutical Ltd. closed 25% short of its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 2.9% and Amgen Inc. remained unchanged.Trading volume totaled 119.3 million shares, compared to the 50-day average of 69.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1191","BK1521","BK1515","HK0000165453.HKD","01177","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2601000009","title":"Sino Biopharmaceutical Stock Climbs 2.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601000009?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:32","pubTimestamp":1767601920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. advanced 2.4% to 6.51 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26347.24.This was the stock's second consecutive day of gains.Sino Biopharmaceutical Ltd. closed 29% below its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 4.8% and Amgen Inc. remained unchanged.Trading volume totaled 101.0 million shares, compared to the 50-day average of 70.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1515","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1589","IE00BZ08YR35.GBP","01177","HK0000165453.HKD"],"gpt_icon":0},{"id":"2600054187","title":"Sino Biopharmaceutical Stock Rallies 2.9% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2600054187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600054187?lang=en_us&edition=fundamental","pubTime":"2026-01-02 16:32","pubTimestamp":1767342720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rose 2.9% to 6.36 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.8% to 26338.47.The stock's rise snapped a six-day losing streak.Sino Biopharmaceutical Ltd. closed 30% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 0.6% and Amgen Inc. remained unchanged.Trading volume totaled 42.9 million shares, compared to the 50-day average of 70.9 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","01177","BK1191","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK1515"],"gpt_icon":0},{"id":"2600030610","title":"Hsin Tse Spends CN¥6.4m On Sino Biopharmaceutical Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2600030610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600030610?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:00","pubTimestamp":1767304820,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical Limited ( HKG:1177 ) shareholders (or potential shareholders) will be happy to see that the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/hsin-tse-spends-cn64m-on-sino-biopharmaceutical-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/hsin-tse-spends-cn64m-on-sino-biopharmaceutical-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","CN","01177","BK1191","IE00BZ08YT58.USD","BK1521","BK1589"],"gpt_icon":0},{"id":"2595672401","title":"Sino Biopharmaceutical Stock Slides 1.6% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2595672401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595672401?lang=en_us&edition=fundamental","pubTime":"2025-12-31 16:32","pubTimestamp":1767169920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. shed 1.6% to 6.18 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25630.54.This was the stock's sixth consecutive day of losses.Sino Biopharmaceutical Ltd. closed 32% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 0.8% and Amgen Inc. remained unchanged.Trading volume totaled 34.7 million shares, compared to the 50-day average of 72.8 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01177","BK1589","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1521","BK1515","IE00BZ08YT58.USD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"1135705524","title":"Sino Biopharm (01177) Completes First Patient Enrollment in Phase III Trial for Its Self-Developed TDI01 \"ROCK2 Inhibitor\" for Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1135705524","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135705524?lang=en_us&edition=fundamental","pubTime":"2025-12-31 12:45","pubTimestamp":1767156303,"startTime":"0","endTime":"0","summary":"Sino Biopharm (01177) announced that the first patient has been enrolled in the Phase III clinical trial for its internally developed TDI01 \"ROCK2 inhibitor,\" intended for the treatment of Idiopathic...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","BK1521","HK0000165453.HKD","IE00BZ08YT58.USD","01177","BK1515","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2595728689","title":"Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2595728689","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595728689?lang=en_us&edition=fundamental","pubTime":"2025-12-31 12:31","pubTimestamp":1767155502,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis . This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL8FGlts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01177","BK1521","HK0000165453.HKD","BK1515","BK1589","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2595788264","title":"Sino Biopharmaceutical Stock Slides 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788264","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595788264?lang=en_us&edition=fundamental","pubTime":"2025-12-29 16:32","pubTimestamp":1766997120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 2.0% to 6.29 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.7% to 25635.23.This was the stock's fourth consecutive day of losses.Sino Biopharmaceutical Ltd. closed 31% short of its 52-week high of HK$9.12, which the company reached Sept. 10.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 2.3% and Amgen Inc. remained unchanged.Trading volume totaled 84.0 million shares, compared to the 50-day average of 74.0 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1521","BK1191"],"gpt_icon":0},{"id":"2595206695","title":"Sino Biopharmaceutical's Psoriasis Drug Meets Goal of Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206695","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595206695?lang=en_us&edition=fundamental","pubTime":"2025-12-29 11:51","pubTimestamp":1766980268,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  said its TQH3906 drug met the main goal of a mid-stage clinical trial, according to a Hong Kong bourse filing Monday.The drug demonstrated \"good safety and tolerability\" in subjects with moderate-to-severe plaque psoriasis, a skin condition.After 12 weeks of treatment, 90% of enrolled subjects achieved over three quarters of improvement in their condition, the firm said.The drug also worked as well as other biologics in the market and was found to be superior to existing marketed oral drugs for psoriasis, Sino Biopharmaceutical said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","01177","BK1191","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK1515"],"gpt_icon":0},{"id":"1170332680","title":"SINO BIOPHARM (01177): TQH3906 \"TYK2/JAK1 JH2 Allosteric Inhibitor\" Achieves Positive Progress in Phase II Clinical Trial for Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=1170332680","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170332680?lang=en_us&edition=fundamental","pubTime":"2025-12-29 06:40","pubTimestamp":1766961641,"startTime":"0","endTime":"0","summary":"SINO BIOPHARM (01177) announced that the group's self-developed National Class 1 innovative drug TQH3906, a \"TYK2/JAK1 JH2 allosteric inhibitor,\" has recently completed its Phase II clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1521","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR","BK1589"],"gpt_icon":0},{"id":"2595727162","title":"Sino Biopharmaceutical Reports Positive Phase II Results for TQH3906 in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595727162?lang=en_us&edition=fundamental","pubTime":"2025-12-29 06:18","pubTimestamp":1766960305,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical Limited has announced positive progress in the Phase II clinical trial of TQH3906, a TYK2/JAK1 JH2 allosteric inhibitor, for the treatment of moderate-to-severe plaque psoriasis. The randomized, double-blind, placebo-controlled, multicenter study demonstrated that TQH3906 met its primary endpoint and exhibited good safety and tolerability across all dose groups. The incidence of adverse events was comparable to placebo, with most events classified as mild or moderate. Detailed data from the study will be presented at upcoming international academic conferences. The company also indicated plans to further investigate TQH3906 for additional indications in autoimmune and dermatological fields, including inflammatory bowel disease and psoriatic arthritis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDL1L7dfB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YS42.EUR","BK1521","BK1589","BK1515","HK0000165453.HKD","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"1125753072","title":"Vice President & Executive Director Xie Xin Increases Stake in SINO BIOPHARM (01177) with 1 Million Shares at HK$6.41 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1125753072","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125753072?lang=en_us&edition=fundamental","pubTime":"2025-12-24 19:26","pubTimestamp":1766575583,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, on December 24, Vice President and Executive Director Xie Xin acquired an additional 1 million shares of SINO BIOPHARM (01177) at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01177","BK1521","HK0000165453.HKD","BK1515","BK1589","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2593498692","title":"Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2593498692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593498692?lang=en_us&edition=fundamental","pubTime":"2025-12-23 16:30","pubTimestamp":1766478600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 6.45 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.1% to 25774.14.This was the stock's second consecutive day of losses.Sino Biopharmaceutical Ltd. closed 29% below its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 7.6% and Amgen Inc. remained unchanged.Trading volume totaled 35.6 million shares, compared to the 50-day average of 78.7 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","BK1589","HK0000165453.HKD","01177","BK1515","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1521","BK1191"],"gpt_icon":0},{"id":"2592750959","title":"Sino Biopharmaceutical Stock Advances 0.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2592750959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592750959?lang=en_us&edition=fundamental","pubTime":"2025-12-18 16:33","pubTimestamp":1766046780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. inched 0.8% higher to 6.49 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25498.13.The stock's rise snapped a three-day losing streak.Sino Biopharmaceutical Ltd. closed 29% short of its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 6.5% and Amgen Inc. remained unchanged.Trading volume totaled 56.7 million shares, compared to the 50-day average of 82.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","IE00BZ08YR35.GBP","BK1589","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD","BK1521","BK1191"],"gpt_icon":0},{"id":"1124928892","title":"Everbright Securities: Focus on Pharmaceutical Sector Recovery and Breakthroughs Amid Innovation Wave","url":"https://stock-news.laohu8.com/highlight/detail?id=1124928892","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124928892?lang=en_us&edition=fundamental","pubTime":"2025-12-16 16:50","pubTimestamp":1765875033,"startTime":"0","endTime":"0","summary":"With China's innovative drug License-out projects setting new records in total value and preclinical projects maintaining a high proportion, emerging therapies such as ADC, bispecific/multispecific...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","BK0095","LU1981816686.USD","BK1583","SG9999014674.SGD","LU1023057109.AUD","LU2580892789.USD","BK0028","LU2495084118.USD","BK0055","BK1515","LU2289578879.USD","BK0196","LU2580892862.HKD","LU1251922891.USD","LU1831875114.USD","01177","BK1500","LU2097828714.EUR","IE00BZ08YT58.USD","BK0077","LU2097828805.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","BK0276","LU0307460666.USD","LU1064130708.USD","LU1719994722.HKD","BK1589","06160","LU0359201885.HKD","LU1969619763.USD","BK1191","BK0188","BK1521","09939","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","BK1588","LU0588546209.SGD","BK1574","LU2097828557.USD","LU0359202008.SGD","161027","LU2148510915.USD","IE00BZ08YS42.EUR","300059","01276","BK0201","LU1997244956.HKD","LU1997245177.USD","LU2543165471.USD","LU0326950275.SGD","159938","LU0359201612.USD","BK1161","LU1064131003.USD","LU1303224171.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2591199436","title":"Sino Biopharmaceutical Stock Slides 4.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591199436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591199436?lang=en_us&edition=fundamental","pubTime":"2025-12-15 16:30","pubTimestamp":1765787400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slid 4.4% to 6.50 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.3% to 25628.88.Sino Biopharmaceutical Ltd. closed 29% below its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 2.0% and Amgen Inc. remained unchanged.Trading volume totaled 94.3 million shares, compared to the 50-day average of 80.6 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1521","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR","BK1589"],"gpt_icon":0},{"id":"2591652812","title":"Insider Stock Buying Reaches CN¥236.0m On Sino Biopharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2591652812","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591652812?lang=en_us&edition=fundamental","pubTime":"2025-12-14 08:12","pubTimestamp":1765671172,"startTime":"0","endTime":"0","summary":"In the last year, multiple insiders have substantially increased their holdings of Sino Biopharmaceutical Limited...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/insider-stock-buying-reaches-cn2360m-on-sino-biopharmaceutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/insider-stock-buying-reaches-cn2360m-on-sino-biopharmaceutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","CN","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","01177","IE00BZ08YT58.USD","HK0000165453.HKD","BK1521","BK1515"],"gpt_icon":0},{"id":"2590508227","title":"Sino Biopharmaceutical's Breast Cancer Drug Gets China Nod for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590508227","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590508227?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:14","pubTimestamp":1765538070,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical's  culmerciclib capsule was approved for marketing by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.The drug is indicated for use in combination with fulvestrant to treat patients with breast cancer who have progressed following prior endocrine therapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ08YR35.GBP","BK1589","HK0000165453.HKD","01177","BK1515","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1521","BK1191"],"gpt_icon":0},{"id":"1161108081","title":"SINO BIOPHARM (01177): Kumorixili Capsule Approved for Market Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1161108081","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161108081?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:58","pubTimestamp":1765529929,"startTime":"0","endTime":"0","summary":"SINO BIOPHARM (01177) announced that its self-developed Class 1 innovative drug, Kumorixili Capsule (brand name: Saitanxin®), has received marketing approval from China's National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","01177","BK1191","IE00BZ08YT58.USD","BK1521","BK1589"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0739},{"period":"1month","weight":0.0089},{"period":"3month","weight":-0.1244},{"period":"6month","weight":0.1592},{"period":"1year","weight":1.3239},{"period":"ytd","weight":0.1052}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.009591},{"month":2,"riseRate":0.681818,"avgChangeRate":0.063302},{"month":3,"riseRate":0.590909,"avgChangeRate":0.048254},{"month":4,"riseRate":0.5,"avgChangeRate":0.025891},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"SINO BIOPHARM","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SINO BIOPHARM(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SINO BIOPHARM(01177) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SINO BIOPHARM,01177,SINO BIOPHARM股票,SINO BIOPHARM股票老虎,SINO BIOPHARM股票老虎国际,SINO BIOPHARM行情,SINO BIOPHARM股票行情,SINO BIOPHARM股价,SINO BIOPHARM股市,SINO BIOPHARM股票价格,SINO BIOPHARM股票交易,SINO BIOPHARM股票购买,SINO BIOPHARM股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SINO BIOPHARM(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SINO BIOPHARM(01177) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}